FY2024 EPS Estimates for ChromaDex Raised by HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for ChromaDex in a report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.06 per share for the year, up from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

Separately, Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday.

ChromaDex Stock Performance

NASDAQ CDXC opened at $6.99 on Tuesday. ChromaDex has a twelve month low of $1.32 and a twelve month high of $7.08. The stock has a market cap of $530.77 million, a PE ratio of 699.00 and a beta of 1.88. The firm has a 50-day simple moving average of $3.70 and a 200 day simple moving average of $3.28.

ChromaDex (NASDAQ:CDXC) last released its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the company earned ($0.01) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BSW Wealth Partners acquired a new position in ChromaDex in the third quarter worth $324,000. WINTON GROUP Ltd bought a new stake in ChromaDex during the 2nd quarter worth about $597,000. SG Americas Securities LLC acquired a new stake in ChromaDex in the 1st quarter valued at about $54,000. Marshall Wace LLP acquired a new stake in ChromaDex in the 2nd quarter valued at about $56,000. Finally, Lazard Asset Management LLC bought a new position in shares of ChromaDex in the first quarter worth about $43,000. 15.41% of the stock is owned by institutional investors.

Insider Buying and Selling at ChromaDex

In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.